Back to Journals » Drug Design, Development and Therapy » Volume 5

Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil™) and granulocyte-colony stimulating factor

Authors Avramova B , Yordanova, Konstantinov, Bobev

Published 26 August 2011 Volume 2011:5 Pages 407—409

DOI https://doi.org/10.2147/DDDT.S19157

Review by Single anonymous peer review

Peer reviewer comments 3



Boryana E Avramova, Maya N Yordanova, Dobrin N Konstantinov, Dragan G Bobev
Specialized Hospital for Treatment of Children with Onco-Haematological Diseases, Sofia, Bulgaria

Abstract: This paper describes the successful mobilization of peripheral blood stem cells for autologous transplantation in three children with malignant diseases by using plerixafor (Mozobil™; Genzyme Corporation, Cambridge, MA) and granulocyte-colony stimulating factor (G-CSF) after failed previous mobilizations. A median sixfold increase in the number of circulating CD34+ cells after plerixafor treatment as compared with the baseline level was observed. An optimal CD34+ cell count for transplantation with one or two leukapheresis sessions was achieved. Mobilization using plerixafor was found to be safe with no adverse events. Therefore, the combination of G-CSF and plerixafor in children results in effective increases in peripheral CD34+ cell counts and reduces the risk of mobilization failure.

Keywords: stem cells, mobilization, plerixafor, children, G-CSF

 

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.